<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="hr">
	<id>https://croatianschoolsydney.com/index.php?action=history&amp;feed=atom&amp;title=Grindeks</id>
	<title>Grindeks - Povijest promjena</title>
	<link rel="self" type="application/atom+xml" href="https://croatianschoolsydney.com/index.php?action=history&amp;feed=atom&amp;title=Grindeks"/>
	<link rel="alternate" type="text/html" href="https://croatianschoolsydney.com/index.php?title=Grindeks&amp;action=history"/>
	<updated>2026-05-21T21:01:43Z</updated>
	<subtitle>Povijest promjena ove stranice na wikiju</subtitle>
	<generator>MediaWiki 1.36.2</generator>
	<entry>
		<id>https://croatianschoolsydney.com/index.php?title=Grindeks&amp;diff=362647&amp;oldid=prev</id>
		<title>WikiSysop: Bot: Automatska zamjena teksta  (-{{cite news +{{Citiranje novina)</title>
		<link rel="alternate" type="text/html" href="https://croatianschoolsydney.com/index.php?title=Grindeks&amp;diff=362647&amp;oldid=prev"/>
		<updated>2021-12-06T02:37:09Z</updated>

		<summary type="html">&lt;p&gt;Bot: Automatska zamjena teksta  (-{{cite news +{{Citiranje novina)&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;hr&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;←Starija inačica&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Inačica od 02:37, 6. prosinca 2021.&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l31&quot;&gt;Redak 31:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Redak 31:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''Grindeks''' (poznat i pod nazivom '''Grindex''')&amp;lt;ref name=grindex/&amp;gt; latvijska je kompanija sa sjedištem u [[Riga|Rigi]]. Proizvodi [[lijek]]ove, [[tableta|tablete]], [[krema|kreme]], [[gel]]ove, sanitetski i liječnički pribor. Osnovana je [[11. listopada]] [[1991.]], a kao [[dioničko društvo]] djeluje od [[25. kolovoza]] [[1997.]]&amp;lt;ref name=&amp;quot;AR2009p3&amp;quot; /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''Grindeks''' (poznat i pod nazivom '''Grindex''')&amp;lt;ref name=grindex/&amp;gt; latvijska je kompanija sa sjedištem u [[Riga|Rigi]]. Proizvodi [[lijek]]ove, [[tableta|tablete]], [[krema|kreme]], [[gel]]ove, sanitetski i liječnički pribor. Osnovana je [[11. listopada]] [[1991.]], a kao [[dioničko društvo]] djeluje od [[25. kolovoza]] [[1997.]]&amp;lt;ref name=&amp;quot;AR2009p3&amp;quot; /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Najpoznatiji Grindeksov proizvod je Meldonium, trgovačkog imena Mildronate&amp;lt;ref&amp;gt;{{eng oznaka}} Biotech Intelligence, [http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html Biotech Intelligence - Mildornate] {{Webarchive|url=https://archive.today/20120719165108/http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html |date=19. srpnja 2012. }}, pristupljeno 17 svibnja 2012.&amp;lt;/ref&amp;gt;&amp;lt;ref name=grindex&amp;gt;{{eng oznaka}} PMR. Pharmaceutical, Healthcare and Medical Sector in Central and Eastern Europe: Industry News, Analyses and Market Data, [http://www.ceepharma.com/63359/Grindex-names-Russian-manufacturing-partner-for-Mildronate.shtml Grindex - Russian manufacturing partner for Mildronate] {{Webarchive|url=https://archive.today/20120728194513/http://www.ceepharma.com/63359/Grindex-names-Russian-manufacturing-partner-for-Mildronate.shtml |date=28. srpnja 2012. }}, pristupljeno 17. svibnja 2012.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Evaluate Pharma, [https://www.evaluatepharma.com/Universal/View.aspx?type=Story&amp;amp;id=137196 Evaluate Pharma - story] {{Webarchive|url=https://archive.is/20121217133224/http://www.evaluatepharma.com/Universal/View.aspx?type=Story&amp;amp;id=137196 |date=17. prosinca 2012. }}, pristupljeno 17. svibnja 2012.&amp;lt;/ref&amp;gt;, koji je [[1970.]] razvio sovjetsko-latvijski [[kemičar]] Ivars Kalviņš. Lijek se prodavao na istočneuropskom tržištu kao lijek protiv [[ishemija|ishemije]].&amp;lt;ref&amp;gt;{{eng oznaka}} [http://www.grindeks.lv/en/for-media/latest-news/Grindeks-meldonium-should-not-be-included-in-the-prohibited-list «Grindeks»: Meldonium should not be included in the Prohibited list] {{Webarchive|url=https://web.archive.org/web/20160312001639/http://www.grindeks.lv/en/for-media/latest-news/Grindeks-meldonium-should-not-be-included-in-the-prohibited-list |date=12. ožujka 2016. }}, ''grindeks.lv'', objavljeno 9. ožujka 2016., pristupljeno 18. travnja 2016.&amp;lt;/ref&amp;gt; No, [[2016.]] godine lijek se našao na popisu zabranjenih lijekova, jer Svjetska anti-doping agencija objavila 124 slučaja zloporabe lijeka radi ostvarivanja boljih športskih rezultata u [[atletika|atletici]], [[tenis]]u, [[hrvanje|hrvanju]], [[boks]]u i [[Umjetničko klizanje|umjetničkom klizanju]].&amp;lt;ref&amp;gt;{{eng oznaka}} {{&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;cite news &lt;/del&gt;|last=Cambers |first=Simon |date=10. ožujka 2016. |title=Why was Maria Sharapova taking meldonium? Her lawyer responds |url=https://amp.theguardian.com/sport/2016/mar/10/maria-sharapova-meldonium-drugs-lawyer-explains |newspaper=[[The Guardian]] |location=[[London]] |access-date=11. ožujka 2016.}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{eng oznaka}} {{Citiranje weba|url=http://en.as.com/en/2016/03/24/other_sports/1458850953_139629.html|title=WADA: 123 failed meldonium tests since January ban|work=en.as.com}}, pristupljeno 18. travnja 2016.&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Najpoznatiji Grindeksov proizvod je Meldonium, trgovačkog imena Mildronate&amp;lt;ref&amp;gt;{{eng oznaka}} Biotech Intelligence, [http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html Biotech Intelligence - Mildornate] {{Webarchive|url=https://archive.today/20120719165108/http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html |date=19. srpnja 2012. }}, pristupljeno 17 svibnja 2012.&amp;lt;/ref&amp;gt;&amp;lt;ref name=grindex&amp;gt;{{eng oznaka}} PMR. Pharmaceutical, Healthcare and Medical Sector in Central and Eastern Europe: Industry News, Analyses and Market Data, [http://www.ceepharma.com/63359/Grindex-names-Russian-manufacturing-partner-for-Mildronate.shtml Grindex - Russian manufacturing partner for Mildronate] {{Webarchive|url=https://archive.today/20120728194513/http://www.ceepharma.com/63359/Grindex-names-Russian-manufacturing-partner-for-Mildronate.shtml |date=28. srpnja 2012. }}, pristupljeno 17. svibnja 2012.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Evaluate Pharma, [https://www.evaluatepharma.com/Universal/View.aspx?type=Story&amp;amp;id=137196 Evaluate Pharma - story] {{Webarchive|url=https://archive.is/20121217133224/http://www.evaluatepharma.com/Universal/View.aspx?type=Story&amp;amp;id=137196 |date=17. prosinca 2012. }}, pristupljeno 17. svibnja 2012.&amp;lt;/ref&amp;gt;, koji je [[1970.]] razvio sovjetsko-latvijski [[kemičar]] Ivars Kalviņš. Lijek se prodavao na istočneuropskom tržištu kao lijek protiv [[ishemija|ishemije]].&amp;lt;ref&amp;gt;{{eng oznaka}} [http://www.grindeks.lv/en/for-media/latest-news/Grindeks-meldonium-should-not-be-included-in-the-prohibited-list «Grindeks»: Meldonium should not be included in the Prohibited list] {{Webarchive|url=https://web.archive.org/web/20160312001639/http://www.grindeks.lv/en/for-media/latest-news/Grindeks-meldonium-should-not-be-included-in-the-prohibited-list |date=12. ožujka 2016. }}, ''grindeks.lv'', objavljeno 9. ožujka 2016., pristupljeno 18. travnja 2016.&amp;lt;/ref&amp;gt; No, [[2016.]] godine lijek se našao na popisu zabranjenih lijekova, jer Svjetska anti-doping agencija objavila 124 slučaja zloporabe lijeka radi ostvarivanja boljih športskih rezultata u [[atletika|atletici]], [[tenis]]u, [[hrvanje|hrvanju]], [[boks]]u i [[Umjetničko klizanje|umjetničkom klizanju]].&amp;lt;ref&amp;gt;{{eng oznaka}} {{&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Citiranje novina &lt;/ins&gt;|last=Cambers |first=Simon |date=10. ožujka 2016. |title=Why was Maria Sharapova taking meldonium? Her lawyer responds |url=https://amp.theguardian.com/sport/2016/mar/10/maria-sharapova-meldonium-drugs-lawyer-explains |newspaper=[[The Guardian]] |location=[[London]] |access-date=11. ožujka 2016.}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{eng oznaka}} {{Citiranje weba|url=http://en.as.com/en/2016/03/24/other_sports/1458850953_139629.html|title=WADA: 123 failed meldonium tests since January ban|work=en.as.com}}, pristupljeno 18. travnja 2016.&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Prema podatcima iz [[2009.]] godine, Grindeks je ostvario [[dobit]] od 76,2 milijuna [[euro|eura]]&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot;/&amp;gt;, od čega 5,078 milijuna eura neto dobiti.&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot;/&amp;gt; Tvrtka je zapošljava 836 radnika&amp;lt;ref name=&amp;quot;AR2009p32&amp;quot;/&amp;gt;, a vlasnici s najvećim udjelom vlasništva su Kirovs Lipmans (33,29%)&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot;/&amp;gt; i Anne Lipmane (16.69%).&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot; /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Prema podatcima iz [[2009.]] godine, Grindeks je ostvario [[dobit]] od 76,2 milijuna [[euro|eura]]&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot;/&amp;gt;, od čega 5,078 milijuna eura neto dobiti.&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot;/&amp;gt; Tvrtka je zapošljava 836 radnika&amp;lt;ref name=&amp;quot;AR2009p32&amp;quot;/&amp;gt;, a vlasnici s najvećim udjelom vlasništva su Kirovs Lipmans (33,29%)&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot;/&amp;gt; i Anne Lipmane (16.69%).&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot; /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>WikiSysop</name></author>
	</entry>
	<entry>
		<id>https://croatianschoolsydney.com/index.php?title=Grindeks&amp;diff=334843&amp;oldid=prev</id>
		<title>WikiSysop: Bot: Automatska zamjena teksta  (-{{cite web +{{Citiranje weba)</title>
		<link rel="alternate" type="text/html" href="https://croatianschoolsydney.com/index.php?title=Grindeks&amp;diff=334843&amp;oldid=prev"/>
		<updated>2021-11-18T01:28:52Z</updated>

		<summary type="html">&lt;p&gt;Bot: Automatska zamjena teksta  (-{{cite web +{{Citiranje weba)&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;hr&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;←Starija inačica&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Inačica od 01:28, 18. studenoga 2021.&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l4&quot;&gt;Redak 4:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Redak 4:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| vrsta              = [[dioničko društvo]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| vrsta              = [[dioničko društvo]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| burzovni_simbol    = OMX: [http://www.nasdaqbaltic.com/market/?pg=details&amp;amp;instrument=LV0000100659&amp;amp;list=2&amp;amp;lang=en GRD1R]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| burzovni_simbol    = OMX: [http://www.nasdaqbaltic.com/market/?pg=details&amp;amp;instrument=LV0000100659&amp;amp;list=2&amp;amp;lang=en GRD1R]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| osnutak            = [[11. listopada]] [[1991.]]&amp;lt;ref name=&amp;quot;AR2009p3&amp;quot;&amp;gt;{{eng oznaka}} {{&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;cite web &lt;/del&gt;|url=http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |title=Joint Stock Company &amp;quot;Grindeks&amp;quot; Annual Report 2009 |publisher=nasdacomxbaltic.com |page=3 |date=27. trvanja 2010. |accessdate=1. studenog 2010. |archiveurl=https://web.archive.org/web/20120309134852/http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |archivedate=9. ožujka 2012. }}, str. 3&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| osnutak            = [[11. listopada]] [[1991.]]&amp;lt;ref name=&amp;quot;AR2009p3&amp;quot;&amp;gt;{{eng oznaka}} {{&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Citiranje weba &lt;/ins&gt;|url=http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |title=Joint Stock Company &amp;quot;Grindeks&amp;quot; Annual Report 2009 |publisher=nasdacomxbaltic.com |page=3 |date=27. trvanja 2010. |accessdate=1. studenog 2010. |archiveurl=https://web.archive.org/web/20120309134852/http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |archivedate=9. ožujka 2012. }}, str. 3&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| prestala_postojati =  &lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| prestala_postojati =  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| osnivači           =  &lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| osnivači           =  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l17&quot;&gt;Redak 17:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Redak 17:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| proizvodi          = [[lijek]]ovi, [[tableta|tablete]], [[krema|kreme]], [[gel]]ovi, sanitetski i liječnički pribor&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| proizvodi          = [[lijek]]ovi, [[tableta|tablete]], [[krema|kreme]], [[gel]]ovi, sanitetski i liječnički pribor&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| usluge             =  &lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| usluge             =  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| prihod             = 76,2 milijuna [[euro|eura]] ([[2009.]])&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot;&amp;gt;{{eng oznaka}} {{&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;cite web &lt;/del&gt;|url=http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |title=Joint Stock Company &amp;quot;Grindeks&amp;quot; Annual Report 2009 |publisher=nasdacomxbaltic.com |page=11 |date=27. travnja 2010. |accessdate=1. studenog 2010. |archiveurl=https://web.archive.org/web/20120309134852/http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |archivedate=9. ožujka 2012. }}, str. 11 (Dobit)&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| prihod             = 76,2 milijuna [[euro|eura]] ([[2009.]])&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot;&amp;gt;{{eng oznaka}} {{&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Citiranje weba &lt;/ins&gt;|url=http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |title=Joint Stock Company &amp;quot;Grindeks&amp;quot; Annual Report 2009 |publisher=nasdacomxbaltic.com |page=11 |date=27. travnja 2010. |accessdate=1. studenog 2010. |archiveurl=https://web.archive.org/web/20120309134852/http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |archivedate=9. ožujka 2012. }}, str. 11 (Dobit)&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| operativni_prihod  =  &lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| operativni_prihod  =  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| neto_dobit         = {{rast}} 5,078 milijuna eura (2009.)&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot; /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| neto_dobit         = {{rast}} 5,078 milijuna eura (2009.)&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot; /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| zaposleni          = 836 (2009.)&amp;lt;ref name=&amp;quot;AR2009p32&amp;quot;&amp;gt;{{eng oznaka}} {{&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;cite web &lt;/del&gt;|url=http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |title=Joint Stock Company &amp;quot;Grindeks&amp;quot; Annual Report 2009 |publisher=nasdacomxbaltic.com |page=32 |date=27. travnja 2010. |accessdate=1. studenog 2010 |archiveurl=https://web.archive.org/web/20120309134852/http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |archivedate=9. ožujka 2012. }}, str. 32&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| zaposleni          = 836 (2009.)&amp;lt;ref name=&amp;quot;AR2009p32&amp;quot;&amp;gt;{{eng oznaka}} {{&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Citiranje weba &lt;/ins&gt;|url=http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |title=Joint Stock Company &amp;quot;Grindeks&amp;quot; Annual Report 2009 |publisher=nasdacomxbaltic.com |page=32 |date=27. travnja 2010. |accessdate=1. studenog 2010 |archiveurl=https://web.archive.org/web/20120309134852/http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |archivedate=9. ožujka 2012. }}, str. 32&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| holding            =  &lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| holding            =  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| divizije           =  &lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| divizije           =  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| podruž             =  &lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| podruž             =  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| vlasnik            = Kirovs Lipmans &amp;lt;small&amp;gt;(33.29%)&amp;lt;/small&amp;gt;&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot;&amp;gt;{{eng oznaka}} {{&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;cite web &lt;/del&gt;|url=http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |title=Joint Stock Company &amp;quot;Grindeks&amp;quot; Annual Report 2009 |publisher=nasdacomxbaltic.com |page=4 |date=27. travnja 2010. |accessdate=1. studenog 2011. |archiveurl=https://web.archive.org/web/20120309134852/http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |archivedate=9. ožujka 2012. }}, str. 4-5&amp;lt;/ref&amp;gt;&amp;lt;br /&amp;gt;Anne Lipmane &amp;lt;small&amp;gt;(16.69%)&amp;lt;/small&amp;gt;&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot; /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| vlasnik            = Kirovs Lipmans &amp;lt;small&amp;gt;(33.29%)&amp;lt;/small&amp;gt;&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot;&amp;gt;{{eng oznaka}} {{&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Citiranje weba &lt;/ins&gt;|url=http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |title=Joint Stock Company &amp;quot;Grindeks&amp;quot; Annual Report 2009 |publisher=nasdacomxbaltic.com |page=4 |date=27. travnja 2010. |accessdate=1. studenog 2011. |archiveurl=https://web.archive.org/web/20120309134852/http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |archivedate=9. ožujka 2012. }}, str. 4-5&amp;lt;/ref&amp;gt;&amp;lt;br /&amp;gt;Anne Lipmane &amp;lt;small&amp;gt;(16.69%)&amp;lt;/small&amp;gt;&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot; /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| slogan             =  &lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| slogan             =  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| web                = [http://www.grindeks.lv/en/ grindeks.lv]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;| web                = [http://www.grindeks.lv/en/ grindeks.lv]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l31&quot;&gt;Redak 31:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Redak 31:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''Grindeks''' (poznat i pod nazivom '''Grindex''')&amp;lt;ref name=grindex/&amp;gt; latvijska je kompanija sa sjedištem u [[Riga|Rigi]]. Proizvodi [[lijek]]ove, [[tableta|tablete]], [[krema|kreme]], [[gel]]ove, sanitetski i liječnički pribor. Osnovana je [[11. listopada]] [[1991.]], a kao [[dioničko društvo]] djeluje od [[25. kolovoza]] [[1997.]]&amp;lt;ref name=&amp;quot;AR2009p3&amp;quot; /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''Grindeks''' (poznat i pod nazivom '''Grindex''')&amp;lt;ref name=grindex/&amp;gt; latvijska je kompanija sa sjedištem u [[Riga|Rigi]]. Proizvodi [[lijek]]ove, [[tableta|tablete]], [[krema|kreme]], [[gel]]ove, sanitetski i liječnički pribor. Osnovana je [[11. listopada]] [[1991.]], a kao [[dioničko društvo]] djeluje od [[25. kolovoza]] [[1997.]]&amp;lt;ref name=&amp;quot;AR2009p3&amp;quot; /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Najpoznatiji Grindeksov proizvod je Meldonium, trgovačkog imena Mildronate&amp;lt;ref&amp;gt;{{eng oznaka}} Biotech Intelligence, [http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html Biotech Intelligence - Mildornate] {{Webarchive|url=https://archive.today/20120719165108/http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html |date=19. srpnja 2012. }}, pristupljeno 17 svibnja 2012.&amp;lt;/ref&amp;gt;&amp;lt;ref name=grindex&amp;gt;{{eng oznaka}} PMR. Pharmaceutical, Healthcare and Medical Sector in Central and Eastern Europe: Industry News, Analyses and Market Data, [http://www.ceepharma.com/63359/Grindex-names-Russian-manufacturing-partner-for-Mildronate.shtml Grindex - Russian manufacturing partner for Mildronate] {{Webarchive|url=https://archive.today/20120728194513/http://www.ceepharma.com/63359/Grindex-names-Russian-manufacturing-partner-for-Mildronate.shtml |date=28. srpnja 2012. }}, pristupljeno 17. svibnja 2012.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Evaluate Pharma, [https://www.evaluatepharma.com/Universal/View.aspx?type=Story&amp;amp;id=137196 Evaluate Pharma - story] {{Webarchive|url=https://archive.is/20121217133224/http://www.evaluatepharma.com/Universal/View.aspx?type=Story&amp;amp;id=137196 |date=17. prosinca 2012. }}, pristupljeno 17. svibnja 2012.&amp;lt;/ref&amp;gt;, koji je [[1970.]] razvio sovjetsko-latvijski [[kemičar]] Ivars Kalviņš. Lijek se prodavao na istočneuropskom tržištu kao lijek protiv [[ishemija|ishemije]].&amp;lt;ref&amp;gt;{{eng oznaka}} [http://www.grindeks.lv/en/for-media/latest-news/Grindeks-meldonium-should-not-be-included-in-the-prohibited-list «Grindeks»: Meldonium should not be included in the Prohibited list] {{Webarchive|url=https://web.archive.org/web/20160312001639/http://www.grindeks.lv/en/for-media/latest-news/Grindeks-meldonium-should-not-be-included-in-the-prohibited-list |date=12. ožujka 2016. }}, ''grindeks.lv'', objavljeno 9. ožujka 2016., pristupljeno 18. travnja 2016.&amp;lt;/ref&amp;gt; No, [[2016.]] godine lijek se našao na popisu zabranjenih lijekova, jer Svjetska anti-doping agencija objavila 124 slučaja zloporabe lijeka radi ostvarivanja boljih športskih rezultata u [[atletika|atletici]], [[tenis]]u, [[hrvanje|hrvanju]], [[boks]]u i [[Umjetničko klizanje|umjetničkom klizanju]].&amp;lt;ref&amp;gt;{{eng oznaka}} {{cite news |last=Cambers |first=Simon |date=10. ožujka 2016. |title=Why was Maria Sharapova taking meldonium? Her lawyer responds |url=https://amp.theguardian.com/sport/2016/mar/10/maria-sharapova-meldonium-drugs-lawyer-explains |newspaper=[[The Guardian]] |location=[[London]] |access-date=11. ožujka 2016.}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{eng oznaka}} {{&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;cite web&lt;/del&gt;|url=http://en.as.com/en/2016/03/24/other_sports/1458850953_139629.html|title=WADA: 123 failed meldonium tests since January ban|work=en.as.com}}, pristupljeno 18. travnja 2016.&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Najpoznatiji Grindeksov proizvod je Meldonium, trgovačkog imena Mildronate&amp;lt;ref&amp;gt;{{eng oznaka}} Biotech Intelligence, [http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html Biotech Intelligence - Mildornate] {{Webarchive|url=https://archive.today/20120719165108/http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html |date=19. srpnja 2012. }}, pristupljeno 17 svibnja 2012.&amp;lt;/ref&amp;gt;&amp;lt;ref name=grindex&amp;gt;{{eng oznaka}} PMR. Pharmaceutical, Healthcare and Medical Sector in Central and Eastern Europe: Industry News, Analyses and Market Data, [http://www.ceepharma.com/63359/Grindex-names-Russian-manufacturing-partner-for-Mildronate.shtml Grindex - Russian manufacturing partner for Mildronate] {{Webarchive|url=https://archive.today/20120728194513/http://www.ceepharma.com/63359/Grindex-names-Russian-manufacturing-partner-for-Mildronate.shtml |date=28. srpnja 2012. }}, pristupljeno 17. svibnja 2012.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Evaluate Pharma, [https://www.evaluatepharma.com/Universal/View.aspx?type=Story&amp;amp;id=137196 Evaluate Pharma - story] {{Webarchive|url=https://archive.is/20121217133224/http://www.evaluatepharma.com/Universal/View.aspx?type=Story&amp;amp;id=137196 |date=17. prosinca 2012. }}, pristupljeno 17. svibnja 2012.&amp;lt;/ref&amp;gt;, koji je [[1970.]] razvio sovjetsko-latvijski [[kemičar]] Ivars Kalviņš. Lijek se prodavao na istočneuropskom tržištu kao lijek protiv [[ishemija|ishemije]].&amp;lt;ref&amp;gt;{{eng oznaka}} [http://www.grindeks.lv/en/for-media/latest-news/Grindeks-meldonium-should-not-be-included-in-the-prohibited-list «Grindeks»: Meldonium should not be included in the Prohibited list] {{Webarchive|url=https://web.archive.org/web/20160312001639/http://www.grindeks.lv/en/for-media/latest-news/Grindeks-meldonium-should-not-be-included-in-the-prohibited-list |date=12. ožujka 2016. }}, ''grindeks.lv'', objavljeno 9. ožujka 2016., pristupljeno 18. travnja 2016.&amp;lt;/ref&amp;gt; No, [[2016.]] godine lijek se našao na popisu zabranjenih lijekova, jer Svjetska anti-doping agencija objavila 124 slučaja zloporabe lijeka radi ostvarivanja boljih športskih rezultata u [[atletika|atletici]], [[tenis]]u, [[hrvanje|hrvanju]], [[boks]]u i [[Umjetničko klizanje|umjetničkom klizanju]].&amp;lt;ref&amp;gt;{{eng oznaka}} {{cite news |last=Cambers |first=Simon |date=10. ožujka 2016. |title=Why was Maria Sharapova taking meldonium? Her lawyer responds |url=https://amp.theguardian.com/sport/2016/mar/10/maria-sharapova-meldonium-drugs-lawyer-explains |newspaper=[[The Guardian]] |location=[[London]] |access-date=11. ožujka 2016.}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{eng oznaka}} {{&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Citiranje weba&lt;/ins&gt;|url=http://en.as.com/en/2016/03/24/other_sports/1458850953_139629.html|title=WADA: 123 failed meldonium tests since January ban|work=en.as.com}}, pristupljeno 18. travnja 2016.&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Prema podatcima iz [[2009.]] godine, Grindeks je ostvario [[dobit]] od 76,2 milijuna [[euro|eura]]&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot;/&amp;gt;, od čega 5,078 milijuna eura neto dobiti.&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot;/&amp;gt; Tvrtka je zapošljava 836 radnika&amp;lt;ref name=&amp;quot;AR2009p32&amp;quot;/&amp;gt;, a vlasnici s najvećim udjelom vlasništva su Kirovs Lipmans (33,29%)&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot;/&amp;gt; i Anne Lipmane (16.69%).&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot; /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Prema podatcima iz [[2009.]] godine, Grindeks je ostvario [[dobit]] od 76,2 milijuna [[euro|eura]]&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot;/&amp;gt;, od čega 5,078 milijuna eura neto dobiti.&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot;/&amp;gt; Tvrtka je zapošljava 836 radnika&amp;lt;ref name=&amp;quot;AR2009p32&amp;quot;/&amp;gt;, a vlasnici s najvećim udjelom vlasništva su Kirovs Lipmans (33,29%)&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot;/&amp;gt; i Anne Lipmane (16.69%).&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot; /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>WikiSysop</name></author>
	</entry>
	<entry>
		<id>https://croatianschoolsydney.com/index.php?title=Grindeks&amp;diff=243108&amp;oldid=prev</id>
		<title>WikiSysop: Bot: Automatski unos stranica</title>
		<link rel="alternate" type="text/html" href="https://croatianschoolsydney.com/index.php?title=Grindeks&amp;diff=243108&amp;oldid=prev"/>
		<updated>2021-10-22T22:46:04Z</updated>

		<summary type="html">&lt;p&gt;Bot: Automatski unos stranica&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Nova stranica&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;lt;!--'''Grindeks'''--&amp;gt;{{Infookvir tvrtka&lt;br /&gt;
| ime                = Grindeks&lt;br /&gt;
| slika              = [[Datoteka:Grindeks Latvia.JPG|260px]]&lt;br /&gt;
| vrsta              = [[dioničko društvo]]&lt;br /&gt;
| burzovni_simbol    = OMX: [http://www.nasdaqbaltic.com/market/?pg=details&amp;amp;instrument=LV0000100659&amp;amp;list=2&amp;amp;lang=en GRD1R]&lt;br /&gt;
| osnutak            = [[11. listopada]] [[1991.]]&amp;lt;ref name=&amp;quot;AR2009p3&amp;quot;&amp;gt;{{eng oznaka}} {{cite web |url=http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |title=Joint Stock Company &amp;quot;Grindeks&amp;quot; Annual Report 2009 |publisher=nasdacomxbaltic.com |page=3 |date=27. trvanja 2010. |accessdate=1. studenog 2010. |archiveurl=https://web.archive.org/web/20120309134852/http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |archivedate=9. ožujka 2012. }}, str. 3&amp;lt;/ref&amp;gt;&lt;br /&gt;
| prestala_postojati = &lt;br /&gt;
| osnivači           = &lt;br /&gt;
| sjedište           = &lt;br /&gt;
| sjedište_grad      = {{ZD|L|LAT}} [[Riga]]&lt;br /&gt;
| sjedište_država    = [[Latvija]]&lt;br /&gt;
| ključna_osoba_titula= Izvršni direktor &lt;br /&gt;
| ključna_osoba       = Kirovs Lipmans&lt;br /&gt;
| konkurencija       = &lt;br /&gt;
| pokriveno_područje = cijeli svijet&lt;br /&gt;
| industrija         = [[ljekarništvo]]&lt;br /&gt;
| proizvodi          = [[lijek]]ovi, [[tableta|tablete]], [[krema|kreme]], [[gel]]ovi, sanitetski i liječnički pribor&lt;br /&gt;
| usluge             = &lt;br /&gt;
| prihod             = 76,2 milijuna [[euro|eura]] ([[2009.]])&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot;&amp;gt;{{eng oznaka}} {{cite web |url=http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |title=Joint Stock Company &amp;quot;Grindeks&amp;quot; Annual Report 2009 |publisher=nasdacomxbaltic.com |page=11 |date=27. travnja 2010. |accessdate=1. studenog 2010. |archiveurl=https://web.archive.org/web/20120309134852/http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |archivedate=9. ožujka 2012. }}, str. 11 (Dobit)&amp;lt;/ref&amp;gt;&lt;br /&gt;
| operativni_prihod  = &lt;br /&gt;
| neto_dobit         = {{rast}} 5,078 milijuna eura (2009.)&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot; /&amp;gt;&lt;br /&gt;
| zaposleni          = 836 (2009.)&amp;lt;ref name=&amp;quot;AR2009p32&amp;quot;&amp;gt;{{eng oznaka}} {{cite web |url=http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |title=Joint Stock Company &amp;quot;Grindeks&amp;quot; Annual Report 2009 |publisher=nasdacomxbaltic.com |page=32 |date=27. travnja 2010. |accessdate=1. studenog 2010 |archiveurl=https://web.archive.org/web/20120309134852/http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |archivedate=9. ožujka 2012. }}, str. 32&amp;lt;/ref&amp;gt;&lt;br /&gt;
| holding            = &lt;br /&gt;
| divizije           = &lt;br /&gt;
| podruž             = &lt;br /&gt;
| vlasnik            = Kirovs Lipmans &amp;lt;small&amp;gt;(33.29%)&amp;lt;/small&amp;gt;&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot;&amp;gt;{{eng oznaka}} {{cite web |url=http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |title=Joint Stock Company &amp;quot;Grindeks&amp;quot; Annual Report 2009 |publisher=nasdacomxbaltic.com |page=4 |date=27. travnja 2010. |accessdate=1. studenog 2011. |archiveurl=https://web.archive.org/web/20120309134852/http://www.nasdaqomxbaltic.com/upload/reports/grd/2009_ar_en_eur_con_ias.pdf |archivedate=9. ožujka 2012. }}, str. 4-5&amp;lt;/ref&amp;gt;&amp;lt;br /&amp;gt;Anne Lipmane &amp;lt;small&amp;gt;(16.69%)&amp;lt;/small&amp;gt;&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot; /&amp;gt;&lt;br /&gt;
| slogan             = &lt;br /&gt;
| web                = [http://www.grindeks.lv/en/ grindeks.lv]&lt;br /&gt;
| dodatak            = &lt;br /&gt;
}}&lt;br /&gt;
'''Grindeks''' (poznat i pod nazivom '''Grindex''')&amp;lt;ref name=grindex/&amp;gt; latvijska je kompanija sa sjedištem u [[Riga|Rigi]]. Proizvodi [[lijek]]ove, [[tableta|tablete]], [[krema|kreme]], [[gel]]ove, sanitetski i liječnički pribor. Osnovana je [[11. listopada]] [[1991.]], a kao [[dioničko društvo]] djeluje od [[25. kolovoza]] [[1997.]]&amp;lt;ref name=&amp;quot;AR2009p3&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Najpoznatiji Grindeksov proizvod je Meldonium, trgovačkog imena Mildronate&amp;lt;ref&amp;gt;{{eng oznaka}} Biotech Intelligence, [http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html Biotech Intelligence - Mildornate] {{Webarchive|url=https://archive.today/20120719165108/http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html |date=19. srpnja 2012. }}, pristupljeno 17 svibnja 2012.&amp;lt;/ref&amp;gt;&amp;lt;ref name=grindex&amp;gt;{{eng oznaka}} PMR. Pharmaceutical, Healthcare and Medical Sector in Central and Eastern Europe: Industry News, Analyses and Market Data, [http://www.ceepharma.com/63359/Grindex-names-Russian-manufacturing-partner-for-Mildronate.shtml Grindex - Russian manufacturing partner for Mildronate] {{Webarchive|url=https://archive.today/20120728194513/http://www.ceepharma.com/63359/Grindex-names-Russian-manufacturing-partner-for-Mildronate.shtml |date=28. srpnja 2012. }}, pristupljeno 17. svibnja 2012.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Evaluate Pharma, [https://www.evaluatepharma.com/Universal/View.aspx?type=Story&amp;amp;id=137196 Evaluate Pharma - story] {{Webarchive|url=https://archive.is/20121217133224/http://www.evaluatepharma.com/Universal/View.aspx?type=Story&amp;amp;id=137196 |date=17. prosinca 2012. }}, pristupljeno 17. svibnja 2012.&amp;lt;/ref&amp;gt;, koji je [[1970.]] razvio sovjetsko-latvijski [[kemičar]] Ivars Kalviņš. Lijek se prodavao na istočneuropskom tržištu kao lijek protiv [[ishemija|ishemije]].&amp;lt;ref&amp;gt;{{eng oznaka}} [http://www.grindeks.lv/en/for-media/latest-news/Grindeks-meldonium-should-not-be-included-in-the-prohibited-list «Grindeks»: Meldonium should not be included in the Prohibited list] {{Webarchive|url=https://web.archive.org/web/20160312001639/http://www.grindeks.lv/en/for-media/latest-news/Grindeks-meldonium-should-not-be-included-in-the-prohibited-list |date=12. ožujka 2016. }}, ''grindeks.lv'', objavljeno 9. ožujka 2016., pristupljeno 18. travnja 2016.&amp;lt;/ref&amp;gt; No, [[2016.]] godine lijek se našao na popisu zabranjenih lijekova, jer Svjetska anti-doping agencija objavila 124 slučaja zloporabe lijeka radi ostvarivanja boljih športskih rezultata u [[atletika|atletici]], [[tenis]]u, [[hrvanje|hrvanju]], [[boks]]u i [[Umjetničko klizanje|umjetničkom klizanju]].&amp;lt;ref&amp;gt;{{eng oznaka}} {{cite news |last=Cambers |first=Simon |date=10. ožujka 2016. |title=Why was Maria Sharapova taking meldonium? Her lawyer responds |url=https://amp.theguardian.com/sport/2016/mar/10/maria-sharapova-meldonium-drugs-lawyer-explains |newspaper=[[The Guardian]] |location=[[London]] |access-date=11. ožujka 2016.}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{eng oznaka}} {{cite web|url=http://en.as.com/en/2016/03/24/other_sports/1458850953_139629.html|title=WADA: 123 failed meldonium tests since January ban|work=en.as.com}}, pristupljeno 18. travnja 2016.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Prema podatcima iz [[2009.]] godine, Grindeks je ostvario [[dobit]] od 76,2 milijuna [[euro|eura]]&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot;/&amp;gt;, od čega 5,078 milijuna eura neto dobiti.&amp;lt;ref name=&amp;quot;AR2009p11&amp;quot;/&amp;gt; Tvrtka je zapošljava 836 radnika&amp;lt;ref name=&amp;quot;AR2009p32&amp;quot;/&amp;gt;, a vlasnici s najvećim udjelom vlasništva su Kirovs Lipmans (33,29%)&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot;/&amp;gt; i Anne Lipmane (16.69%).&amp;lt;ref name=&amp;quot;AR2009p4&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Izvori ==&lt;br /&gt;
{{izvori}}&lt;br /&gt;
&lt;br /&gt;
== Vanjske poveznice ==&lt;br /&gt;
* {{lav oznaka}}  [https://web.archive.org/web/20110202153949/http://www.grindeks.lv/en grindeks.lv - službene stranice tvrtke]&lt;br /&gt;
&lt;br /&gt;
[[Kategorija:Gospodarstvo Latvije]]&lt;br /&gt;
[[Kategorija:Riga]]&lt;br /&gt;
[[Kategorija:Farmaceutske tvrtke]]&lt;/div&gt;</summary>
		<author><name>WikiSysop</name></author>
	</entry>
</feed>